Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Adjustment of VINX Benchmark Index due to rights issue in NIBE Industrier AB The Rights Offering for NIBE Industrier AB (NIBE B, SE0008321293) has an ex-date of Tuesday, October 4, 2016. Each...
-
The monthly review of the NASDAQ OMX Iceland Benchmark Bond Indexes has now been completed. The new composition will be effective as of Monday, October 3, 2016. There are no changes in...
-
Adjustment of VINX Benchmark Index due to extraordinary dividend in Citycon Oyj The following information is based on a press release from Citycon Oyj (CTY1S, FI0009002471) published on September...
-
The monthly review of the NASDAQ OMX Iceland Benchmark Bond Indexes has now been completed. The new composition will be effective as of Thursday, September 1, 2016. There are no changes in...
-
Adjustment of VINX Benchmark Index due to extraordinary dividend in Marine Harvest ASA The following information is based on a press release from Marine Harvest ASA (MHG, NO0003054108) published...
-
Adjustment of VINX Benchmark Index due to extraordinary dividend in DFDS A/S The following information is based on a press release from DFDS A/S (DFDS, DK0060655629) published on August 18,...
-
The following information is based on a press release from Mylan N.V. published on August 02, 2016. It is announced that Mylan N.V. has over 90 percent of the total amount of shares in Meda AB...
-
The monthly review of the NASDAQ OMX Iceland Benchmark Bond Indexes has now been completed. The new composition will be effective as of Tuesday, August 2, 2016. The following change in...
-
The monthly review of the NASDAQ OMX Iceland Benchmark Bond Indexes has now been completed. The new composition will be effective as of Friday, July 1, 2016. There are no changes in constituents....
-
The semi-annual review of the VINX 30 Index has now been completed. As a result of the review, Genmab (GEN) will be added, whereas A.P. Moller – Maersk B (MAERSK B) will be removed from the...